Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu
  • quotes

  • charts

  • technicals

  • company

Regen Biopharma Inc (RGBPP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0100 +100.00%
on 08/10/18
0.0245 -18.37%
on 07/23/18
+0.0044 (+28.21%)
since 07/16/18
3-Month
0.0100 +100.00%
on 08/10/18
0.0351 -43.02%
on 05/17/18
-0.0101 (-33.55%)
since 05/16/18
52-Week
0.0100 +100.00%
on 08/10/18
0.0900 -77.78%
on 11/21/17
-0.0125 (-38.46%)
since 08/16/17

Most Recent Stories

More News
No Toxicity Seen in Mice as Regen BioPharma, Inc. Finishes Initial Optimization of its Lead NR2F6 Small Molecule Agonist

Regen BioPharma Inc.'s (OTCQB: RGBP) and (OTCQB: RGBPP) lead candidate drug, RG-NAE005, was tested for its maximum tolerated dose in mice and showed no signs of toxicity. Regen has methodically optimized...

RGBP : 0.0150 (-7.41%)
RGBPP : 0.0200 (unch)
Entest Group, Inc. Declares Property Dividend of 3,000,000 Common Shares of Zander Therapeutics Inc.

On May 10, 2018, Entest Group, Inc. (OTC: ETNI) declared the distribution on a pro rata basis as a dividend in kind of 3,000,000 of the common shares of Zander Therapeutics, Inc., par value $0.0001, currently...

RGBP : 0.0150 (-7.41%)
RGBPP : 0.0200 (unch)
ETNI : 0.0278 (unch)
Regen BioPharma, Inc. Nears Completion of Optimizing its Lead NR2F6 Small Molecule Agonist

SAN DIEGO , March 21, 2018 /PRNewswire/ --

RGBP : 0.0150 (-7.41%)
RGBPP : 0.0200 (unch)
Regen BioPharma, Inc. Nears Completion of Optimizing its Lead NR2F6 Small Molecule Agonist

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has been methodically optimizing small molecules that bind to, and activate, the NR2F6 nuclear receptor. The process is close to completion, with the...

RGBP : 0.0150 (-7.41%)
RGBPP : 0.0200 (unch)
Cancer Immunotherapy Technology Projected to Create Further Growth

According to data provided by Allied Market Research, the global cancer immunotherapy market is expected to grow to $117.14 billion by 2022, growing at a CAGR of 14.5 percent from the time period of 2016...

CLDX : 0.43 (+2.38%)
ARQL : 6.27 (+5.03%)
RGBP : 0.0150 (-7.41%)
RGBPP : 0.0200 (unch)
ECYT : 17.14 (+3.94%)
CASI : 7.43 (-2.24%)
Regen BioPharma's Chief Scientific Officer Explains the Link Between its NR2F6 Medicinal Chemistry and Three-Dimensional X-Ray Structure Programs

SAN DIEGO , November 8, 2017 /PRNewswire/ --

RGBP : 0.0150 (-7.41%)
RGBPP : 0.0200 (unch)
Regen BioPharma's Chief Scientific Officer Explains the Link Between its NR2F6 Medicinal Chemistry and Three-Dimensional X-Ray Structure Programs

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) recently began a program to determine the three-dimensional structure of the NR2F6 nuclear receptor. In addition, the Company recently reported that...

RGBP : 0.0150 (-7.41%)
RGBPP : 0.0200 (unch)
Regen BioPharma, Inc. Announces Former Eli Lilly Executive and Current CVS Board Member will Lead Newly Formed Business Advisory Board (BAB)

Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) announced that former Eli Lilly executive Jean-Pierre Millon will serve as chairman of its newly formed business advisory board (BAB). The Company...

RGBP : 0.0150 (-7.41%)
LLY : 104.58 (+1.21%)
RGBPP : 0.0200 (unch)
Regen BioPharma, Inc. Announces Former Eli Lilly Executive and Current CVS Board Member will Lead Newly Formed Business Advisory Board (BAB)

SAN DIEGO , October 30, 2017 /PRNewswire/ --

RGBP : 0.0150 (-7.41%)
RGBPP : 0.0200 (unch)
Regen BioPharma, Inc. Begins Program to Determine the 3-Dimensional Crystal Structure of NR2F6

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has begun a program to determine the 3-dimensional structure of NR2F6 both with and without the Company's proprietary small molecule drugs bound to...

RGBP : 0.0150 (-7.41%)
RGBPP : 0.0200 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade RGBPP with:

Key Turning Points

2nd Resistance Point 0.0200
1st Resistance Point 0.0200
Last Price 0.0200
1st Support Level 0.0200
2nd Support Level 0.0200

See More

52-Week High 0.0900
Fibonacci 61.8% 0.0594
Fibonacci 50% 0.0500
Fibonacci 38.2% 0.0406
Last Price 0.0200
52-Week Low 0.0100

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar